Noxopharm Limited (ASX:NOX)
Share Pricing & News Healthcare

AUD 0.16

-0.005 (3.03%)
(As on 2022-11-26 20:06:56 AEDT)
Previous Close Open Close*
0.165 0.17 0.16
Market Cap Dividend Yield (Annualized)
AUD 46.758M 0.00%

Day Range
0.16L 0.175 H
52 WEEK HIGH LOW
0.135L 0.495 H

Chart Price & Information

Last Trade 0.16
Change% -3.0303
52 W H/L 0.495/0.135
EBITDA -18.328M
NPAT After Abnormal Items -18.667M
Equity 24.118M
ROE% -77.40%
Total Liabilities 2.476M
Total Revenue 5.429M
Cash and Cash Equivalents 14.011M

Stock Information

Share price 0.16
Market Cap 46.758M
Price/Gross Cash Flow -4.46
Dividend Yield Excluding Special 0.00%
Ending Shares 292.238M
52-Week Range 0.495-0.135
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 3.040
Net Tangible Asset (NTA) 0.08
P/E ratio 32.895
Sector P/E --
EPS -6.41
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.04
Net Gearing -57.43%
Sales Per Share 0.00
Book Value Per Share 0.08

Similar Companies

Related Articles

About Company

Noxopharm Limited is an ASX-listed clinical-stage drug development company focused on the potential treatment of a wide range of cancers. The company operates under the healthcare sector and aims to create unique anti-cancer drugs. It is backed by a solid pipeline of drug candidates including Veyonda®, the first oncology pipeline product. Housed in the non-oncology subsidiary, Nyrada Inc. are four pre-clinical R and D programs.

Corporate Information


Suite 3 Level 4, 828 Pacific Highway, GORDON, NSW, AUSTRALIA, 2072

Phone:(02) 9144 2223

Website:http://www.noxopharm.com

Dividends

Ex-Date Net Dividend Frank Flag Period End Date Type Payable

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2023-09-25 2023
Report (Prelim) 2023-08-24 2023
Report (Interim) 2023-02-20 2023